In order to treat AS and RA, Enzene Biosciences has started selling biosimilar adalimumab commercially in India.

0
418
WhatsApp D. Pharma Group Join Now
Telegram D. Pharma Group Join Now
Telegram Group Latest Pharma Jobs Join Now
Telegram B. Pharma Group Join Now
Telegram Medicine Update Group Join Now
WhatsApp B. Pharma/ GPAT Channel Join Now

Adalimumab has started to be sold commercially for the treatment of rheumatoid arthritis and ankylosing spondylitis, according to Enzene Biosciences Ltd., a technology-focused biotechnology business based in Pune. This is the business’s fourth biosimilar launch in recent years, and the company thinks that this first commercial launch utilising continuous manufacturing technology would help in lowering the cost of RA therapy for millions of patients throughout India.

When it comes to improving the accessibility of therapies for a variety of critical disorders like cancer, rheumatoid arthritis, osteoporosis, etc., biosimilar medications play a significant role. Unfortunately, despite the availability of biosimilars, access to these medications is still restricted because of their high cost. This is because the traditional biologics production method is quite expensive. One of the pioneers in the development of a fully integrated platform for continuous production is Enzene. The company asserts that because its new platform delivers several times more volumetric productivity than traditional production procedures, their biosimilars can further break down the price barrier.

The commercialization of adalimumab is proof of the innovation-based workplace culture at Enzene Biosciences, said Dr. Himanshu Gadgil, CEO of the company. “We have been working on this innovative fully integrated platform for the previous six years. Enzene intends to increase this platform’s accessibility on a worldwide scale through our CDMO vertical. Ankylosing spondylitis, commonly known as Marie-Strumpell disease or Bechterew’s illness, was the subject of comparative efficacy and safety studies during the development of the drug adalimumab. In the past 18 months, the business has introduced a total of four biosimilar products.

The managing director of Alkem Labs, Sandeep Singh, stated, “We have made considerable investments to create a world-class biotech company through Enzene, and our confidence has been validated by a number of biosimilar launches in recent years. We are now in a position to have a substantial impact on Indian healthcare because to Alkem’s remarkable expertise in the clinical development of complicated treatments.

LEAVE A REPLY

Please enter your comment!
Please enter your name here